I n 2007, the American College of Cardiology/American Heart Association guidelines first recommended perioperative volatile anesthetic use in patients at risk for myocardial ischemia. 1 numerous animal studies from canines to nematodes provided evidence for volatile anesthetic protection against ischemia-reperfusion (hypoxia-reoxygenation) injury. 2, 3 Several clinical trials conducted in patients undergoing coronary artery bypass grafting suggested the experimental study results translated into clinically relevant cardioprotection. 4 However, almost a decade later, the primary molecular mechanisms mediating volatile anesthetic-induced cardioprotection still remain to be identified. In this month's issue of AneStHe-SIology, Wojtovich et al. 5 aim to provide novel insight into this limitation by deciphering the identity of a cardiac myocyte mitochondrial potassium channel that mediates volatile anesthetic-induced preconditioning. By using a genetic knock-out approach in mice, the authors identify the Slo2 gene family encoded potassium channel subtype Slo2.1 in cardiac myocyte mitochondria as a key determinant of volatile anesthetic-induced preconditioning from myocardial ischemia-reperfusion injury. 5 Both Slo2.1 (Kcnt2/'Slick') and Slo2.2 (Kcnt1/'Slack') are potassium channels activated by increased intracellular sodium levels and belong to the "big" conductance K + channel (BK) family. The newly identified localization of Slick in cardiac myocyte mitochondria may add another piece to the puzzle of mitochondrial ion channels apparently involved in the complex response of cardiomyocytes to ischemia-reperfusion injury, including the mitochondrial AtP-sensitive K + channel, the mitochondrial permeability transitional pore, and other BK channels that are long recognized in mediating volatile anesthetic-induced preconditioning via regulation of mitochondrial function. 6 Although initial reports suggested that a Ca 2+ -activated BK channel (likely Slo1) was responsible for anesthetic preconditioning, 7-9 the fact that Slo1 −/− mice can still be preconditioned by isoflurane, 10 coupled with the results of the study by Wojtovich et al., suggest reevaluation of these early findings.
In their present study, Wojtovich et al. report for the first time evidence that volatile anestheticinduced K + flux is abolished in cardiac myocyte mitochondria isolated from mice lacking Slick (Slo2.1 −/− ). Subsequently, isoflurane-induced preconditioning effects were absent in Slo2.1 −/− mice but not in Slo2.2 −/− mice subjected to myocardial ischemiareperfusion injury. By demonstrating Slo2.1-mediated protective effects of volatile anesthetics that are independent of ischemia or pharmacologic K + channel openers, the authors provide specificity for a novel molecular target for volatile anesthetic specific effects.
Thus, in the era of precision medicine, this study may provide us with more extensive knowledge to which patients undergoing cardiac surgery will benefit from receiving volatile anesthetics to reduce ischemia-reperfusion injury. The recommendations of the 2007 American College of Cardiology/ American Heart Association guidelines have been continuously modified to downplay the powerful effects that volatile anesthetics have in reducing myocardial injury in preclinical models. In 2011, the recommendations for patients undergoing coronary artery bypass graft surgery were changed to only recommend the use of volatile anesthetics to facilitate extubation in cardiac patients. 11 Further, the 2014 guidelines for patients undergoing noncardiac surgery recommend similarly the use of either volatile or intravenous agents. 12 Primary endpoints such as a reduction in postoperative troponin levels or improved cardiac function were often met only in elective and highly selective cardiac patient populations 4 
"Technology is moving in the direction where one day there may be a 'preconditioning gene panel' that is run on every patient preoperatively to customize choice of anesthetic regimen for surgery."
Image: ©Thinkstock. remained nonevident or controversial in patient populations undergoing noncardiac surgery. 13, 14 numerous reasons may explain the clear lack of translation from experimental models to heterogeneous patient populations. Conditions such as diabetes likely attenuate the ability to precondition the myocardium and medications such as AtP-sensitive K + channel channel inhibitors, used clinically to manage diabetes, may further block the effects of volatile anesthetics. 14 Intravenous agents including opioids may also synergistically act with volatile anesthetics to reduce myocardial injury. 15 Advances in patient care are urgently needed to reduce perioperative myocardial reperfusion injury. numerous preclinical studies provide a wealth of promising data on how volatile anesthetics or strategies like remote ischemic preconditioning effectively exert myocardial protection. Although the latter involves different mechanisms and requires additional molecular mediators, 16 recently published results from two large studies show that remote ischemic conditioning strategies fail in providing benefit to patients. 17, 18 These data add to the litany of agents and interventions proposed to limit reperfusion injury that have failed in the clinic, including even cyclosporine A. 19 The controversial data from clinical trials, however, must bring us back to better understand underlying molecular and cellular mechanisms in the basic science laboratory. technology is moving in the direction where one day there may be a "preconditioning gene panel" that is run on every patient preoperatively to customize choice of anesthetic regimen for surgery. Candidate genes specific to volatile anesthetics, as that identified in the current manuscript, move us one step closer to identifying novel mechanisms to address the shortcomings of failed clinical translation.
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